Simultaneous occurrence of HER2 mutation and PD-L1 high expression in EGFR-mutant NSCLC: a case report
- 1Department of Medical Oncology, The Second Affiliated Hospital of Fujian Medical University
- 2Department of Respiratory and Critical Care Medicine, Quanzhou First Hospital
Abstract
In non-small cell lung cancer (NSCLC), EGFR and HER2 mutations are generally considered mutually exclusive events, with a co-occurrence probability estimated to be less than 1%. Patients with either EGFR or HER2 mutations tend to exhibit low PD-L1 expression levels. The simultaneous presence of both EGFR and HER2 mutations accompanied by high PD-L1 expression is exceedingly rare. This study reports a female patient who was admitted to the hospital after a routine physical examination revealed a right lung nodule and was diagnosed with “right lung adenocarcinoma (cT2aN2aM1c1, IVA; EGFR 21 L858R mutation; HER2 exon 8 mutation; PD-L1 TPS 60%).” The patient was immediately started on first-line third-generation EGFR-targeted therapy (Furmonertinib), but disease progression occurred after just 4.4 months (malignant pleural effusion and pericardial effusion). As the patient refused repeat biopsy, treatment with an ADC drug (Trastuzumab rezetecan) was initiated. Disease control was achieved after only one cycle of treatment, and the regimen was continued thereafter. The progression-free survival has exceeded 5.3 months, and at the time of writing this report, the disease remained well-controlled. This paper presents the first report of this rare and therapeutically challenging combination of molecular pathological features—concurrent EGFR and HER2 mutations with high PD-L1 expression in an NSCLC patient. When standard first-line third-generation EGFR-TKIs proved ineffective, the successful use of an anti-HER2 ADC drug to control the tumor demonstrates its potential clinical value. However, whether all patients initially presenting with this pathological molecular subtype will achieve consistent efficacy remains to be further investigated.
Related
- Complete loss of all mismatch repair protein expression in endometrioid carcinoma: A first case report of null phenotype induced by MLH1 hypermethylation and MSH2 somatic mutation
- Case Report: Durable response to tislelizumab monotherapy in microsatellite-stable, BRAF V600E-mutant right-sided colon cancer with extremely high PD-L1 expression
- 445 Co-mutation architecture shapes immunotherapy outcomes in KRAS-mutant NSCLC: real-world evidence from AACR GENIE BPC cohort
- More Than Half of DNMT3A-Mutant Patients in Pooled Public Cancer Genomic Data Carry No Tumor-Derived Mutation: Clonal Hematopoiesis Introduced by Patient-Keyed Aggregation
- High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)
BibTeX
@article{su2026simultaneous,
title = {{Simultaneous occurrence of HER2 mutation and PD-L1 high expression in EGFR-mutant NSCLC: a case report}},
author = {Yunxia Su and Huanzhang Su and Jianguang Lin},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1953767},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1953767/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Simultaneous occurrence of HER2 mutation and PD-L1 high expression in EGFR-mutant NSCLC: a case report
AU - Yunxia Su
AU - Huanzhang Su
AU - Jianguang Lin
PY - 2026
DA - 2026/10/15
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1953767
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1953767/full
AB - In non-small cell lung cancer (NSCLC), EGFR and HER2 mutations are generally considered mutually exclusive events, with a co-occurrence probability estimated to be less than 1%. Patients with either EGFR or HER2 mutations tend to exhibit low PD-L1 expression levels. The simultaneous presence of both EGFR and HER2 mutations accompanied by high PD-L1 expression is exceedingly rare. This study reports a female patient who was admitted to the hospital after a routine physical examination revealed a right lung nodule and was diagnosed with “right lung adenocarcinoma (cT2aN2aM1c1, IVA; EGFR 21 L858R mutation; HER2 exon 8 mutation; PD-L1 TPS 60%).” The patient was immediately started on first-line third-generation EGFR-targeted therapy (Furmonertinib), but disease progression occurred after just 4.4 months (malignant pleural effusion and pericardial effusion). As the patient refused repeat biopsy, treatment with an ADC drug (Trastuzumab rezetecan) was initiated. Disease control was achieved after only one cycle of treatment, and the regimen was continued thereafter. The progression-free survival has exceeded 5.3 months, and at the time of writing this report, the disease remained well-controlled. This paper presents the first report of this rare and therapeutically challenging combination of molecular pathological features—concurrent EGFR and HER2 mutations with high PD-L1 expression in an NSCLC patient. When standard first-line third-generation EGFR-TKIs proved ineffective, the successful use of an anti-HER2 ADC drug to control the tumor demonstrates its potential clinical value. However, whether all patients initially presenting with this pathological molecular subtype will achieve consistent efficacy remains to be further investigated.
SN - 2234-943X
ER -